Cristina Donini
YOU?
Author Swipe
View article: Correction: Chemoprevention of malaria with long-acting oral and injectable drugs: an updated target product profile
Correction: Chemoprevention of malaria with long-acting oral and injectable drugs: an updated target product profile Open
View article: Chemoprevention of malaria with long-acting oral and injectable drugs: an updated target product profile
Chemoprevention of malaria with long-acting oral and injectable drugs: an updated target product profile Open
Malaria is preventable, but the burden of disease remains high with over 249 million cases and 608,000 deaths reported in 2022. Historically, the most important protective interventions have been vector control and chemopreventive medicine…
View article: Efficacy, Safety, Tolerability, and Pharmacokinetics of MMV390048 in Acute Uncomplicated Malaria
Efficacy, Safety, Tolerability, and Pharmacokinetics of MMV390048 in Acute Uncomplicated Malaria Open
An open label, phase IIa study conducted in Ethiopia evaluated the efficacy, safety, tolerability, and pharmacokinetics of a single 120-mg dose of the phosphatidylinositol 4-kinase inhibitor MMV390048 in Plasmodium vivax malaria. The study…
View article: Malarial <scp>PI4K</scp> inhibitor induced diaphragmatic hernias in rat: Potential link with mammalian kinase inhibition
Malarial <span>PI4K</span> inhibitor induced diaphragmatic hernias in rat: Potential link with mammalian kinase inhibition Open
Background MMV390048 is an aminopyridine plasmodial PI4K inhibitor, selected as a Plasmodium blood‐stage schizonticide for a next generation of malaria treatments to overcome resistance to current therapies. MMV390048 showed an acceptable …
View article: Concentration‐QT modelling of the novel DHFR inhibitor P218 in healthy male volunteers
Concentration‐QT modelling of the novel DHFR inhibitor P218 in healthy male volunteers Open
Aims Given the increasing emergence of drug resistance in Plasmodium , new antimalarials are urgently required. P218 is an aminopyridine that inhibits dihydrofolate reductase being developed as a malaria chemoprotective drug. Assessing the…
View article: Chemoprotective Antimalarial Activity of P218 against Plasmodium falciparum: A Randomized, Placebo-Controlled Volunteer Infection Study
Chemoprotective Antimalarial Activity of P218 against Plasmodium falciparum: A Randomized, Placebo-Controlled Volunteer Infection Study Open
P218 is a highly selective dihydrofolate reductase inhibitor with potent in vitro activity against pyrimethamine-resistant Plasmodium falciparum . This single-center, randomized, double-blind, placebo-controlled phase Ib study evaluated P2…
View article: A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the <i>Plasmodium</i> Phosphatidylinositol 4-Kinase Inhibitor MMV390048
A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the <i>Plasmodium</i> Phosphatidylinositol 4-Kinase Inhibitor MMV390048 Open
Background MMV390048 is the first Plasmodium phosphatidylinositol 4-kinase inhibitor to reach clinical development as a new antimalarial. We aimed to characterize the safety, pharmacokinetics, and antimalarial activity of a tablet formulat…
View article: First‐in‐human clinical trial to assess the safety, tolerability and pharmacokinetics of P218, a novel candidate for malaria chemoprotection
First‐in‐human clinical trial to assess the safety, tolerability and pharmacokinetics of P218, a novel candidate for malaria chemoprotection Open
Aims This first‐in‐human clinical trial of P218, a novel dihydrofolate reductase inhibitor antimalarial candidate, assessed safety, tolerability, pharmacokinetics and food effects in healthy subjects. Methods The study consisted of two par…
View article: Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel <i>Plasmodium</i> Phosphatidylinositol 4-Kinase Inhibitor MMV390048 in Healthy Volunteers
Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel <i>Plasmodium</i> Phosphatidylinositol 4-Kinase Inhibitor MMV390048 in Healthy Volunteers Open
MMV390048 is a novel antimalarial compound that inhibits Plasmodium phosphatidylinositol-4-kinase. The safety, tolerability, pharmacokinetic profile, and antimalarial activity of MMV390048 were determined in healthy volunteers in three sep…
View article: Erratum for Brunschwig et al., “UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria”
Erratum for Brunschwig et al., “UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria” Open
View article: UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria
UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria Open
The 2-aminopyridine MMV048 was the first drug candidate inhibiting Plasmodium phosphatidylinositol 4-kinase (PI4K), a novel drug target for malaria, to enter clinical development. In an effort to identify the next generation of PI4K inhibi…
View article: Antimalarial efficacy of MMV390048, an inhibitor of <i>Plasmodium</i> phosphatidylinositol 4-kinase
Antimalarial efficacy of MMV390048, an inhibitor of <i>Plasmodium</i> phosphatidylinositol 4-kinase Open
MMV390048, a member of a new class of inhibitors of the Plasmodium phosphatidylinositol 4-kinase, shows potential for both treatment and prophylaxis.
View article: ELQ-300 Prodrugs for Enhanced Delivery and Single-Dose Cure of Malaria
ELQ-300 Prodrugs for Enhanced Delivery and Single-Dose Cure of Malaria Open
ELQ-300 is a preclinical candidate that targets the liver and blood stages of Plasmodium falciparum , as well as the forms that are crucial to transmission of disease: gametocytes, zygotes, and ookinetes. A significant obstacle to the clin…